User profiles for Piers Patten
 | Piers PattenClinical Senior Lecturer, King's College London Verified email at kcl.ac.uk Cited by 4241 |
[HTML][HTML] Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective …
…, A Rigg, J Spicer, MH Malim, P Fields, P Patten… - The Lancet …, 2021 - thelancet.com
Background The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients with
cancer is unknown. We aimed to assess the safety and immunogenicity of the BNT162b2 (…
cancer is unknown. We aimed to assess the safety and immunogenicity of the BNT162b2 (…
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
…, AJM Ferreri, T Teshima, PEM Patten… - Nature medicine, 2022 - nature.com
Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor-T cell therapy with
clinically meaningful outcomes demonstrated in patients with relapsed/refractory (r/r) B-cell …
clinically meaningful outcomes demonstrated in patients with relapsed/refractory (r/r) B-cell …
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
Given advanced age, comorbidities, and immune dysfunction, chronic lymphocytic leukemia
(CLL) patients may be at particularly high risk of infection and poor outcomes related to …
(CLL) patients may be at particularly high risk of infection and poor outcomes related to …
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two …
Background Genome-edited donor-derived allogeneic anti-CD19 chimeric antigen receptor
(CAR) T cells offer a novel form of CAR-T-cell product that is available for immediate clinical …
(CAR) T cells offer a novel form of CAR-T-cell product that is available for immediate clinical …
CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment
PEM Patten, AGS Buggins, J Richards… - Blood, The Journal …, 2008 - ashpublications.org
Chronic lymphocytic leukemia (CLL) is a lymphoproliferative disease with a highly variable
outcome. The prognosis of patients with CLL may be predicted using a number of biomarkers…
outcome. The prognosis of patients with CLL may be predicted using a number of biomarkers…
A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease
…, C Calissano, S Marsilio, PEM Patten… - Blood, The Journal …, 2011 - ashpublications.org
Chronic lymphocytic leukemia (CLL) is an incurable adult disease of unknown etiology.
Understanding the biology of CLL cells, particularly cell maturation and growth in vivo, has been …
Understanding the biology of CLL cells, particularly cell maturation and growth in vivo, has been …
[HTML][HTML] Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study
…, A Pettitt, JG Gribben, PEM Patten… - Journal of clinical …, 2019 - ncbi.nlm.nih.gov
PURPOSE The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by
targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (…
targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (…
Chronic lymphocytic leukemia therapy guided by measurable residual disease
…, R de Tute, A Rawstron, PEM Patten… - … England Journal of …, 2024 - Mass Medical Soc
… Rawstron, PEM Patten, and P. Hillmen, for the National Cancer Research Institute Chronic
Lymphocytic Leukemia … D., Piers EM Patten, Ph.D., FRCP, and Peter Hillmen, MB, Ch.B., Ph.…
Lymphocytic Leukemia … D., Piers EM Patten, Ph.D., FRCP, and Peter Hillmen, MB, Ch.B., Ph.…
[PDF][PDF] Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients
…, A Rigg, S Papa, AC Hayday, PEM Patten… - Cancer cell, 2021 - cell.com
Given the immune system's importance for cancer surveillance and treatment, we have
investigated how it may be affected by SARS-CoV-2 infection of cancer patients. Across some …
investigated how it may be affected by SARS-CoV-2 infection of cancer patients. Across some …
[HTML][HTML] Poor outcome and prolonged persistence of SARS‐CoV‐2 RNA in COVID‐19 patients with haematological malignancies; King's College Hospital experience
…, P Krishnamurthy, P Patten… - British Journal of …, 2020 - ncbi.nlm.nih.gov
2. Thachil J. What do monitoring platelet counts in COVID-19 teach us? J Thromb Haemost.
2020. https://doi. org/10.1111/jth. 14879 3. Pavord S, Thachil J, Hunt BJ, Murphy M, Lowe G, …
2020. https://doi. org/10.1111/jth. 14879 3. Pavord S, Thachil J, Hunt BJ, Murphy M, Lowe G, …